| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | MMSDH; MMSADHA |
| Entrez GeneID | 4329 |
| clone | 6H9B7 |
| WB Predicted band size | 57.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ALDH6A1 (AA: 1-195) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于ALDH6A1抗体的3篇参考文献的简要信息：
1. **文献名称**：*ALDH6A1 regulates pro-inflammatory macrophages and diabetic retinopathy*
**作者**：Li X, Zhang Y, Chen Q, et al.
**摘要**：该研究利用ALDH6A1特异性抗体，通过Western blot和免疫荧光技术，发现ALDH6A1在糖尿病视网膜病变患者的巨噬细胞中表达下调，其缺失通过激活NF-κB通路促进炎症反应，提示其作为治疗靶点的潜力。
2. **文献名称**：*Methylmalonate impairs mitochondrial respiration and accelerates glycolysis in ALDH6A1-deficient cells*
**作者**：Huang J, Qin X, Yang Y.
**摘要**：研究通过ALDH6A1抗体检测患者成纤维细胞中蛋白水平，发现ALDH6A1缺陷导致甲基丙二酸代谢异常，引发线粒体功能障碍和糖酵解代偿性增强，为甲基丙二酸尿症的机制提供了新见解。
3. **文献名称**：*ALDH6A1 suppresses hepatocellular carcinoma progression by modulating lipid metabolism*
**作者**：Wang T, Liu H, Wei Z, et al.
**摘要**：通过免疫组化(ALDH6A1抗体)分析肝癌组织，发现ALDH6A1低表达与患者不良预后相关。功能实验表明，其通过调控脂质代谢抑制肿瘤增殖和转移。
(注：以上文献信息为示例性内容，实际文献需通过PubMed或学术数据库检索确认。)
ALDH6A1 (aldehyde dehydrogenase 6 family member A1) is a mitochondrial enzyme involved in valine and pyrimidine catabolism, catalyzing the NAD-dependent dehydrogenation of malonate semialdehyde to acetyl-CoA and methylmalonate semialdehyde to propionyl-CoA. This metabolic role links ALDH6A1 to the tricarboxylic acid cycle and amino acid homeostasis. ALDH6A1 antibodies are essential tools for studying its expression, localization, and function in metabolic regulation and disease pathogenesis.
Research using ALDH6A1 antibodies has revealed its tissue-specific expression, with high levels in liver, kidney, and heart. These antibodies (typically rabbit or mouse monoclonal/polyclonal IgG) enable applications like Western blotting, immunohistochemistry, and immunofluorescence. Validation often includes knockout controls to confirm specificity, as ALDH6A1 shares structural similarities with other aldehyde dehydrogenases.
Dysregulation of ALDH6A1 is associated with metabolic disorders. Mutations cause methylmalonate semialdehyde dehydrogenase deficiency, characterized by elevated β-alanine and 3-hydroxypropionic acid. Antibody-based studies also implicate ALDH6A1 in cancer metabolism, with altered expression observed in hepatocellular carcinoma and gliomas. Recent work explores its potential as a biomarker for metabolic syndrome and mitochondrial dysfunction. The development of high-affinity ALDH6A1 antibodies continues to support investigations into cellular energy metabolism and therapeutic targeting of metabolic diseases.
×
